Search

Findings about proteins called molecular chaperones are shedding new light on possible approaches to cancer treatment.

… Thursday, November 10, 2016 Summary New research has shown that proteins called molecular chaperones work together in a communal relationship, suggesting new avenues for targeting their activity. Highlights Molecular chaperones help coordinate important activities inside cells.   Researchers are developing

Eight leading cancer centers are coming together to share genomic sequencing data, in the hope of making faster progress in curing cancer.

… Thursday, January 5, 2017 Summary A collaboration among eight leading cancer centers, including MSK, is aiming to take advantage of genomic sequencing of patient tumors to advance the field of precision oncology. On January 5, the group is announcing the release of data on nearly 19,000 cancer patients

Dr. Emmanouil Pappou urges the importance of routine cancer screenings, even during COVID-19, on the TODAY Show.

… Wednesday, November 18, 2020 Fear of COVID-19 has kept people of all ages from getting their routine cancer screenings, including mammograms and colonoscopies . However, rescheduling these vital screenings could be lifesaving. According to the American Cancer Society , more than 150,000 new cases of

Learn more about how MSK is developing new treatments for osteosarcoma and other bone cancers.

… Wednesday, September 14, 2016 Summary MSK is leading the way in osteosarcoma treatment, developing new surgical methods that enable many people to be cured and to live full, active lives. Highlights Osteosarcomas are rare tumors; two-thirds of them occur in children and young adults. They most frequently

Researchers from Memorial Sloan Kettering Cancer Center (MSK), in collaboration with an international research team, have discovered that DNA circles can contribute to the development of childhood cancers. The team, led by MSK computational biologist Richard Koche and Anton Henssen of Charité University Hospital Berlin, made this discovery by studying extrachromosomal DNA in neuroblastoma cells. Neuroblastoma develops in immature nerve cells and is the most common form of cancer in infants.

… Monday, December 16, 2019 Researchers from Memorial Sloan Kettering Cancer Center (MSK), in collaboration with an international research team, have discovered that DNA circles can contribute to the development of childhood cancers. The team, led by MSK computational biologist Richard Koche and Anton

An antibody test developed at MSK could shed light on the immune response to the COVID-19 virus.

… Tuesday, September 22, 2020 Summary A test developed by MSK researchers can detect three different antibodies to the COVID-19 virus. The test could help researchers clarify how someone fights off the virus, as well as who might be best protected if they are exposed a second time. Testing for antibodies

Blood pressure should be monitored closely and on an ongoing basis for several months after initiating ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL), according to our retrospective study.

… Wednesday, January 8, 2020 Blood pressure should be monitored closely and on an ongoing basis for several months after initiating ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL), according to our retrospective study published this month in JAMA Network Open . Hypertension is a

根据我们的回顾性研究，在慢性淋巴细胞白血病 (CLL) 患者开始接受伊鲁替尼治疗后，应密切监测其血压，并持续数月。

… Wednesday, January 8, 2020 根据我们本月发表在《美国医学会杂志网络公开》 (JAMA Network Open) 上的回顾性研究，在慢性淋巴细胞白血病 (CLL) 患者开始接受伊鲁替尼治疗后，应密切监测其血压，持续数月。 高血压是临床试验中接受伊鲁替尼治疗的 CLL 患者发生的常见不良事件。我们在非临床试验环境中研究了 CLL 患者中与伊鲁替尼相关的高血压的发展模式、管理策略和长期血管影响。  (1) 我们的结果显示，在接受伊鲁替尼治疗的 247 例 CLL 患者的整个队列中，包括存在和不存在高血压病史的患者，患者的血压均发生显著升高。 我们的结果显示，在接受伊鲁替尼治疗的

… Monday, March 24, 2025 Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and progress.  (1) Metastatic disease develops in about 50% of patients with surgically

Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune checkpoint blocker avelumab (Bavencio®) and the tyrosine kinase inhibitor (TKI) axitinib (Inlyta®) can significantly improve progression-free survival (PFS) in people who have been previously untreated for advanced renal cell carcinoma (RCC).

… Sunday, October 21, 2018 Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology ’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune